Company Overview and News

4
CVSI / CV Sciences, Inc. / Mona Michael Joseph Jr - SCHEDULE 13D AMENDMENT (Activist Investment)

2018-06-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVSI

7
CVSI / CV Sciences, Inc. / Mona Michael Joseph Jr - SCHEDULE 13D AMENDMENT (Activist Investment)

2018-06-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVSI

63
CVSI / CV Sciences, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-08 fintel.io
CV Sciences, Inc. (OTC:CVSI) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,700,092 shares. Largest shareholders include Mona Michael III, Panagora Asset Management Inc, and Hilton Capital Management, LLC. CV Sciences, Inc. (OTC:CVSI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
CVSI VBLT CANV ALDR VBLTF

4
CVSI / CV Sciences, Inc. / Mona Michael III - SCHEDULE 13D (Activist Investment)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
CVSI

10
CVSI / CV Sciences, Inc. / Mona Michael III - SCHEDULE 13D (Activist Investment)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
CVSI

3
CV Sciences, Inc. Supports World No Tobacco Day on May 31, 2018

2018-05-31 globenewswire
LAS VEGAS, May 31, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), is pleased to announce its support in highlighting the World Health Organization (WHO) and its partners in the annual World No Tobacco Day on May 31, 2018. This year, the theme is "Tobacco Breaks Hearts,” referencing a study that tobacco is responsible for more than one in ten deaths caused by cardiovascular disease.
CVSI

3
CV Sciences, Inc. to Present at 8th Annual LD Micro Invitational on June 4-6, 2018 in Bel-Air, California

2018-05-22 globenewswire
LAS VEGAS, May 22, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the leading brand of hemp extract products, PlusCBD Oil™, announced today that it will be presenting at the 8th Annual LD Micro Invitational, being held at the Luxe Sunset Boulevard Hotel in Bel-Air, California on June 4-6, 2018.
CVSI

166
30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP TRTCD CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB IIPR.PRA POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF

3
CV Sciences, Inc. to Host First Quarter 2018 Financial Results Conference Call on Tuesday, May 15, 2018

2018-05-08 globenewswire
LAS VEGAS, May 08, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (OTCQB:CVSI) a preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a conference call to discuss its first quarter 2018 financial results on Tuesday, May 15, 2018 at 1:15pm PT / 4:15pm ET.
CVSI

44
Alcohol Stocks Fighting To Stay Relevant In A Marijuana Stock Market?

2018-04-27 seekingalpha
For 30 days the marijuana industry has seen some of the biggest government support to date.
CVSI STZ.B TWMJF BUD WEED ACAN AHBIF HEMP STZ SAM DEO SMG

3
CV Sciences, Inc. Fully Retires Convertible Debt

2018-04-25 globenewswire
LAS VEGAS, April 25, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) announced today that it has negotiated and prepaid the remaining balance due under its March 1, 2017 Convertible Promissory Note (the “Note”) in cash, thus avoiding the lender’s conversion of this amount under the terms of the Note. The Note represented the last remaining convertible debt instrument outstanding.
CVSI

3
CV Sciences, Inc. Announces Silver Level Sponsorship of the 15th Annual Nutrition and Health Conference in Boston, Massachusetts - April 29-May 2, 2018

2018-04-18 globenewswire
Company Continues its Expansion into the Healthcare Professional Market through One-on-One Education, Exclusive Product Offerings and Enhanced Practitioner Support.
CVSI

3
CV Sciences, Inc. Repays Installment Obligation on Convertible Debt

2018-04-04 globenewswire
LAS VEGAS, April 04, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today that it has paid the April 2018 installment obligation under its March 1, 2017 Convertible Promissory Note (the “Note”) in cash, thus avoiding the lender’s conversion of this amount under the terms of the Note. The Company issued the Note on March 1, 2017 in the original principal amount of $770,000, which provided the Company the right to satisfy installment obligations in cash or by conversion of the installment amount into shares of our Common Stock at a price determined upon the trading price of our stock during the period immediately prior to conversion.
CVSI

5
CV Sciences, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-04-02 seekingalpha
The following slide deck was published by CV Sciences, Inc. in conjunction with their 2017 Q4 earnings call.
CVSI

CVSI : CV Sciences Stock Analysis and Research Report

2017-11-20 - Asif

CV Sciences was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas on December 9, 2010. On July 25, 2013, the Company’s predecessor, CannaVest Corp., a Texas corporation (“CannaVest Texas”), merged with the Company, a wholly-owned Delaware subsidiary of CannaVest Texas, to effectuate a change in the Company’s state of incorporation from Texas to Delaware. On January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the State of Delaware, reflecting its corporate name change to “CV Sciences, Inc.”, effective on January 5, 2016. In addition, on January 4, 2016, the Company amended its Bylaws to reflect its corporate name change to “CV Sciences, Inc.” The Company previously operated under the corporate name of CannaVest Corp. On June 8, 2016, the Company changed its trading symbol from CANV to CVSI, and continues to be traded on the OTC: QB. The change in corporate name was undertaken in conn...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 126654102